NCT02861859 - Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study | Biotech Hunter

Enrollment

221

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 23, 2019

Study Completion Date

December 23, 2019

Conditions

Breast Cancer

Interventions

DRUG

Olanzapine

Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.

DRUG

Olanzapine Placebo

Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.

Trial Locations (1)

The Ottawa Hospital Research Institute Cance Center, Ottawa